Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed, a biopharmaceutical company, will host a virtual R&D Day on September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET. The event will highlight updates on pipeline candidates, including treprostinil palmitil and brensocatib, as well as advancements for ARIKAYCE (amikacin liposome inhalation suspension). Dr. Ronald J. Oudiz will present during the event. The conference call will be accessible live and recorded for later viewing. Insmed focuses on serious and rare diseases with its innovative therapies.
Insmed Incorporated (Nasdaq:INSM) announced participation in three virtual investor conferences in September 2020. Management will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020. Each presentation will be streamed live, accessible on the company's investor relations webpage and archived for 30 days. Insmed focuses on treatments for serious rare diseases, including its product ARIKAYCE®.
Insmed announced the publication of final results from the Phase 2 WILLOW study for brensocatib, a treatment for non-cystic fibrosis bronchiectasis (NCFBE), in the New England Journal of Medicine. Findings showed significant improvement in time to first pulmonary exacerbation compared to placebo, with risk reductions of 42% and 38% for two dosages. The treatment was well tolerated, with manageable adverse events. Insmed aims to initiate a Phase 3 program for brensocatib by year-end 2020, highlighting the urgency for therapeutic options in NCFBE.
Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 12 new employees as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, these awards include options to purchase a total of 84,520 shares at an exercise price of $28.17 per share, which is the closing price on September 1, 2020. The options come with a ten-year term and a four-year vesting schedule, aimed at incentivizing employee retention and commitment to the company.
Insmed Incorporated (Nasdaq: INSM) has granted inducement awards to 11 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards, approved by the Compensation Committee, consist of options to purchase a total of 76,960 shares of Insmed common stock at an exercise price of $27.15 per share, based on the closing price on August 3, 2020. The options are valid for a ten-year term and will vest over four years, promoting employee retention and commitment to the company.
Insmed reported strong Q2 2020 results, achieving $42.5 million in total revenue, up from $30.0 million in Q2 2019. U.S. sales of ARIKAYCE reached $41.0 million, reflecting growth amidst COVID-19 challenges. The company also reported a net loss of $61.9 million or $0.64 per share, improving from a $66.5 million loss in the prior year. Notably, brensocatib received FDA Breakthrough Therapy Designation, and ARIKAYCE gained a positive opinion from the CHMP for treating NTM lung infections, signaling potential market expansion.
Insmed Incorporated (NASDAQ: INSM) will announce its second quarter 2020 financial results on August 6, 2020. A conference call for investors is scheduled for 8:30 a.m. ET on the same day, aimed at discussing the financial outcomes and offering a business update. Interested parties can join by calling (888) 317-6003 for domestic or (412) 317-6061 for international access, referencing conference ID 9359069. The call will also be available via live webcast on Insmed's official website.
Insmed has received a positive opinion from the CHMP for ARIKAYCE Liposomal 590 mg, aimed at treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in adults with limited treatment options. A final decision from the European Commission is expected in the second half of 2020. This recommendation follows promising results from the Phase 3 CONVERT study, showing improved sputum culture conversion rates when ARIKAYCE is used with a multi-drug regimen. If approved, ARIKAYCE would be the first approved therapy for this condition in both Europe and the United States.
Insmed Incorporated (Nasdaq: INSM) announced on July 6, 2020, the granting of inducement awards to 11 new employees. These awards, approved by Insmed's Compensation Committee, consist of options to purchase a total of 66,400 shares of common stock at an exercise price of $29.19 per share, the closing price on the date of grant (July 1, 2020). The options have a ten-year term and a four-year vesting schedule. Insmed is focused on transforming the lives of patients with serious and rare diseases, with ARIKAYCE® as its first commercial product for treating MAC lung disease.
Insmed announced final results from the Phase 2 WILLOW study of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE). The study met its primary endpoint, showing significant prolongation of time to first pulmonary exacerbation versus placebo (p=0.027 for 10 mg; p=0.044 for 25 mg). Notably, the 10 mg group had a 42% reduction in exacerbation risk. The treatment was well-tolerated, with the most common adverse events being cough and headache. Following these results, Insmed plans to initiate a Phase 3 program for brensocatib in bronchiectasis in the second half of 2020.